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Background: Although modified live virus (MLV) vaccines are commonly used for porcine reproductive and respiratory
syndrome virus (PRRSV) control, there have been safety concerns due to the quick reversion of MLV to virulence during
replication in pigs. Previous studies have demonstrated that mutant viruses emerged from lethal mutagenesis driven
by antiviral mutagens and that those viruses had higher genetic stability compared to their parental strains because
they acquired resistance to random mutation. Thus, this strategy was explored to stabilize the PRRSV genome in the
current study.
Results: Four antiviral mutagens (ribavirin, 5-fluorouracil, 5-azacytidine, and amiloride) were evaluated for their antiviral
effects against VR2332, a prototype of type 2 PRRSV. Among the mutagens, ribavirin and 5-fluorouracil had significant
antiviral effects against VR2332. Consequently, VR2332 was serially passaged in MARC-145 cells in the presence of
ribavirin at several concentrations to facilitate the emergence of ribavirin-resistant mutants. Two ribavirin-resistant
mutants, RVRp13 and RVRp22, emerged from serial passages in the presence of 0.1 and 0.2 mM ribavirin, respectively.
The genetic stability of these resistant mutants was evaluated in MARC-145 cells and compared with VR2332. As
expected, the ribavirin-resistant mutants exhibited higher genetic stability compared to their parental virus.
Conclusions: In summary, ribavirin and 5-fluorouracil effectively suppressed PRRSV replication in MARC-145 cells.
However, ribavirin-resistant mutants emerged when treated with low concentrations (≤0.2 mM) of ribavirin, and those
mutants were genetically more stable during serial passages in cell culture.
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Porcine Reproductive and Respiratory Syndrome (PRRS)
is one of the most economically important infectious
diseases of swine worldwide. The annual loss associated
with PRRS to the United States swine industry has been es-
timated to be approximately 664 million USD [1]. PRRS
virus (PRRSV), the etiological agent of PRRS, is classified as
a member of the Arteriviridae virus family, along with
equine arteritis virus (EAV), lactate dehydrogenase-elevating
virus (LDV) of mice, and simian hemorrhagic fever virus
(SHFV), and belongs to the order Nidovirales [2,3]. PRRSV
is a small, enveloped virus that contains a single-stranded,
non-segmented, positive-sense RNA genome approximately* Correspondence: kwi0621@jbnu.ac.kr
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unless otherwise stated.15 kb in length. The PRRSV genome encodes at least
ten open reading frames (ORFs) designated as ORF1a,
ORF1b, ORF2a, ORF2b, ORF3, ORF4, ORF5a, ORF5,
ORF6, and ORF7 [4-8]. Because PRRSV evolves very
quickly [9,10], there is a great deal of genetic variability
among PRRSV strains. In general, PRRSV strains are
grouped into European (type 1) and North American
(type 2) genotypes [11-13], but high levels of genetic
variability still exist among viruses, even within the
same genotype [10,14,15], which results in suboptimal
cross-protection between different PRRSV strains and
becomes a significant impediment to the development
of effective vaccines. Modified live virus (MLV) vac-
cines have been most commonly used to control
PRRSV because they confer better protection against
homologous virus strains compared to inactivated or
recombinant vaccines [16]. However, there have been. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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because they quickly revert to virulence during serial
passages in pigs [17-21]. Therefore, it is important to de-
velop a new strategy to stabilize the PRRSV genome dur-
ing virus replication for the purpose of vaccine safety.
Previously, a number of nucleoside analogs, including riba-
virin (guanosine analog) [22,23], 5-fluorouracil (pyrimidine
analog) [24], and 5-azacytidine (cytidine analog) [25],
have been shown to be mutagenic, antiviral compounds
that are effective against various RNA viruses, such as
foot-and-mouth disease virus (FMDV), poliovirus, and
hepatitis C virus (HCV). These mutagens increase the
mutation frequency of RNA viruses above a tolerable
error threshold during replication, ultimately driving
viral infection into extinction [26-35]. Amiloride hydro-
chloride hydrate (hereafter “amiloride”) is another anti-
viral drug with efficacy against many RNA viruses,
including rhinovirus, coxsackievirus B3 (CVB3), coro-
naviruses, flaviviruses, and retroviruses [36-40]. More-
over, it has been demonstrated that amiloride increases
the mutation frequency of RNA viruses, in addition to
its other antiviral activities [41]. It has also been dem-
onstrated that mutant viruses that emerged following
sequential passages of HCV, CVB3, poliovirus, and
FMDV [41-44] in the presence of ribavirin had higher
genetic stability than wild-type viruses. Therefore, this
strategy was employed to select a mutagen-resistant
strain of PRRSV that would have higher genetic stabil-
ity. In the current study, the effects of four mutagens
(ribavirin, 5-fluorouracil, 5-azacytidine, and amiloride)
on PRRSV replication in MARC-145 cells were evalu-
ated to select the mutagen that is most effective against
PRRSV. Then, mutagen-resistant viruses were rescued
after sequential passages in the presence of the muta-
gen and were evaluated for their genetic stability during
additional sequential passages in cell culture systems.
Methods
Antiviral mutagens
Ribavirin (Sigma-Aldrich, St. Louis, MO, USA), 5-
fluorouracil (Sigma-Aldrich), 5-azacytidine (Sigma-Aldrich),
and amiloride (Sigma-Aldrich) were used in this study. All
of these mutagens were dissolved in RPMI-1640 medium
(Sigma-Aldrich) at stock concentrations of 15 mM
(ribavirin) and 20 mM (5-fluorouracil, 5-azacytidine,
and amiloride), sterile-filtered using a 0.22-μm syringe
filter, aliquoted, and stored at −20°C until use.
Virus and cell culture
VR2332, a prototype strain of PRRSV type 2, was used
in the study. MARC-145, an African Green Monkey kid-
ney cell line highly permissive to PRRSV infection, was
used for PRRSV propagation and antiviral assays.
MARC-145 cells were maintained in RPMI-1640medium supplemented with heat-inactivated 10% fetal
bovine serum (FBS, Invitrogen, Carlsbad, CA, USA),
2 mM L-glutamine, and 100× antibiotic-antimycotic solu-
tion [Anti-anti, Invitrogen; 1× solution contains 100 IU/ml
penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml Fungi-
zone® (amphotericin B)] (hereafter referred to as “RPMI
growth medium”) at 37°C in a humidified 5% CO2
atmosphere.
Evaluation of effects of mutagens on PRRSV replication
Confluent monolayers of MARC-145 cells were prepared
in 25-cm2 flasks and were inoculated with VR2332 at a
multiplicity of infection (MOI) of 0.01. After incubation
for 1 hour in a humidified 5% CO2 incubator at 37°C,
the virus inoculum was removed, and the cell monolayer
was replenished with RPMI growth medium containing
one of the antiviral mutagens. Ribavirin, 5-fluorouracil,
and amiloride were evaluated at six different concentra-
tions (0, 0.2, 0.4, 0.6, 0.8, and 1 mM), while 5-azactytidine
was evaluated at ten different concentrations (0, 0.0001,
0.001, 0.01, 0.1, 0.2, 0.4, 0.6, 0.8, and 1 mM), based on pre-
vious reports [45,46]. The treated flasks were then incu-
bated for four more days under the same culture
conditions described above, during which time cell culture
medium was collected from each flask every 24 hours,
centrifuged, and stored at −80°C until analysis.
Virus titration assay
Progeny virus titers were determined using a microtitra-
tion infectivity assay [47]. In brief, up to 8, 10-fold serial
dilutions of samples were prepared. Confluent mono-
layers of MARC-145 cells prepared in 96-well plates
were inoculated in quadruplicate with 100 μl of each
sample and were incubated for 1 hour under the same
culture conditions described above. After incubation, the
inoculum was discarded, and the cell monolayer was
replenished with RPMI growth medium. The plates were
then incubated for an additional six days and monitored
for cytopathic effects (CPE) daily. The titer of each virus
sample was calculated based on CPE and was expressed
as a 50% tissue culture infective dose (TCID50)/ml [48].
Cytotoxicity assay
A commercially available cytotoxicity assay kit (Cyto-
Tox-Glo™, Promega, Fitchburg, Wisconsin, USA) was
used to assess the cytotoxic effects of the four antiviral
mutagens in MARC-145 cells. In short, the CytoTox-
Glo™ assay measures a distinct protease (dead-cell prote-
ase) activity associated with cytotoxicity [49]. The assay
uses a luminogenic peptide substrate (alanyl-alanylphe-
nylalanyl-aminoluciferin; AAF-Glo™ substrate) to meas-
ure the activity of dead-cell protease released from cells
that have lost membrane integrity. To determine the cy-
totoxicities of the mutagens, confluent monolayers of
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ing, the cells were replenished with RPMI growth medium
containing one of the mutagens at one of four different
concentrations (0, 0.5, 1, and 1.5 mM) and further incu-
bated under the culture conditions described above. Super-
natants were collected from each flask every 12 hours for
up to 48 hours, and the levels of luminescence (RLU)
generated from the cleavage of luminogenic AAF-Glo™ sub-
strate by protease in the collected supernatants were mea-
sured to determine the cytotoxicity levels induced by each
mutagen according to the manufacturer’s instructions.
Serial passages of PRRSV in MARC-145 cells in the
presence of ribavirin
VR2332 was serially passaged in cell culture in the pres-
ence of 0, 0.05, 0.1, 0.2, 0.3, 0.5, or 0.7 mM ribavirin to
study the emergence of ribavirin-resistant PRRSV mu-
tants. Confluent monolayers of MARC-145 cells were
prepared in 6-well plates and pre-treated with RPMI
growth medium containing ribavirin for 7 hours prior to
infection at 37°C. After the pre-treatment incubation,
cells were inoculated with VR2332 at an MOI of 0.01.
After incubation for 1 hour, virus inoculum was re-
moved, and cells were replenished with RPMI growth
medium containing the same concentrations of ribavirin
as described above for post-treatment. The infection was
then allowed to proceed for 24 hours, after which the
cell culture fluid was collected from each well, centri-
fuged, and stored at −80°C until use. The supernatant
from each passage became the inoculum for the next
passage. This procedure was repeated a total of 22 times.
Assessment of growth kinetics for ribavirin-resistant mutants
in the presence of ribavirin at several concentrations using
multi-step growth curve analysis
The growth competencies of two ribavirin-resistant can-
didate mutants (RVRp13 and RVRp22) were assessed in
MARC-145 cells in the presence of ribavirin, compared
to VR2332 in the presence of ribavirin. Confluent mono-
layers of MARC-145 cells were prepared in 25-cm2
flasks, inoculated with each virus at an MOI of 0.01, and
incubated for 1 hour under the same conditions de-
scribed above. After incubation, the inoculum was dis-
carded, and cells were replenished with RPMI-1640
growth medium containing several concentrations (0,
0.1, 0.2, 0.3, 0.4, and 0.5 mM) of ribavirin. The treated
flasks were then incubated for 4 more days. Superna-
tants were collected from each flask every 24 hours, and
the virus in these supernatants was titered.
Assessment of genetic stability of ribavirin-resistant
mutants during passages in MARC-145 cells
To assess the genetic stability of the ribavirin-resistant
mutants (RVRp13 and RVRp22) that arose fromsequential passages of VR2332 in the presence of ribavi-
rin as described above, the mutant viruses were passaged
10 more times, along with VR2332. Plaque purification
was performed using each strain to achieve a highly
homogenous virus clone, as described previously [17].
For each passage, confluent MARC-145 cell monolayer
prepared in 6-well plates were inoculated with each virus
strain and incubated for 1 hour. After incubation, the
cells were replenished with RPMI growth medium and
incubated for 24 hours. Then, supernatants were col-
lected and used for the next passage of cells. This pro-
cedure was repeated 10 times.
Plaque purification was conducted on the supernatants
collected after 10 passages to isolate 15 plaque clones
per viral strain. Viral RNA was extracted from each virus
clone using a commercial kit (Ribo_spin vRD™, GeneAll,
Seoul, South Korea) according to the manufacturer’s in-
structions. nsp2 and ORF5, which are known to be the
most variable regions in the PRRSV genome [12,14,50-54],
were amplified with a one-step RT-PCR kit (Takara Bio
Inc., Otsu, Shiga, Japan) and were submitted for sequen-
cing (Macrogen Inc., South Korea). PCR amplification and
sequencing primers are shown in Table 1.
Data analysis
The effects of the four mutagens on PRRSV replication
were analyzed by repeated measures analysis of variance
(ANOVA). The Wilcoxon signed-rank test was used to
compare the mutation rates of the ribavirin-resistant
mutants with that of their parental virus strain. Nucleo-
tide sequences were aligned and analyzed using Laser-
gene® MagAlign software (DNASTAR Inc., Madison, WI,
USA).
Results
Effects of antiviral mutagens on in vitro PRRSV replication
The effects of the four antiviral mutagens studied on
PRRSV replication are summarized in Figure 1. The rate
of VR2332 replication in MARC-145 cells decreased
more than 100-fold in the presence of 0.2 mM ribavirin
and was completely suppressed at concentrations of ri-
bavirin higher than 0.2 mM. Despite the efficient anti-
viral effect of ribavirin at low concentrations, no
significant cytotoxicity was observed, even at the highest
concentration (1.5 mM) of ribavirin studied, up to
48 hours post-treatment {Figure 1 (A and B)}. Similarly,
5-fluorouracil suppressed VR2332 replication in a dose-
dependent manner: the rate of VR2332 replication de-
creased approximately 100-fold or more than 1000-fold
in the presence of 0.2 or 1 mM 5-fluorouracil, respect-
ively. No significant cytotoxicity was observed with up
to 1.5 mM 5-fluorouracil {Figure 1 (C and D)}. However,
significant levels of cytotoxicity were observed with 1
and 1.5 mM azacytidine at 48 hours post-treatment,
Table 1 Sequences of primers used for PCR amplification and sequencing of the nsp2 and ORF5 regions in the VR2332
genome





1a 1481R 1463-1481 GGGAGTAGTGTTTGAGGTG
1a 1366F 1366-1383 CTCTTGTGCGACTGCTAC
1a 2115R 2097-2115 TACAGGTCAATCTTTGCTG
1a 2058F 2058-2075 CCCAGAACAAAACCAACC
1a 2867R 2850-2867 ATTGCGGTGAGGACACAA
1a 2771F 2771-2788 TGGGAAGATTTGGCTGTT
1a 3581R 3563-3581 CAATGGTAAGGTCGCTCTC
1a 3511F 3511-3529 TCCGTGTGAGTTTGTGATG
1a 4276R 4258-4276 CAGTAACCTGCCAAGAATG







a: Location of primers in the full-length VR2332 genome (GenBank accession [AY150564]). p: primers used for PCR amplification and sequencing. The remaining
primers were used only for sequencing. r: reference primers used in a previous study [17].
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pressed when at least 0.1 mM 5-azacytidine was in-
cluded in the culture medium {Figure 1 (E and F)}. No
significant antiviral activity against VR2332 was mea-
sured at low concentrations (<0.1 mM) of 5-azacytidine
(data not shown). Similarly, high concentrations (1 and
1.5 mM) of amiloride also caused significant cytotox-
icity in MARC-145 cells after 36 hours post-treatment
{Figure 1 (H)}; however, VR2332 replication was sup-
pressed by amiloride in a dose-dependent manner and
was completely suppressed by more than 0.6 mM
amiloride {Figure 1 (G)}. Based on these results, ribavi-
rin was selected for further experiments because it was
most effective at suppressing PRRSV replication with-
out causing significant cytotoxicity in MARC-145 cells.
Emergence of ribavirin-resistant mutants after serial
passage of PRRSV in MARC-145 cells in the presence of
ribavirin
VR2332 was serially passaged in MARC-145 cells in the
presence of ribavirin at concentrations of 0, 0.05, 0.1,
0.2, 0.3, 0.5, and 0.7 mM. Although 0.05 mM ribavirin
failed to mediate significant suppression of VR2332 rep-
lication, concentrations of 0.1 and 0.2 mM ribavirin were
able to suppress virus replication to undetectable levels
based on a virus titration assay at passage 2. However,
virus replication started to resume at passages 5 and 17
in the presence of 0.1 and 0.2 mM ribavirin, respectively.
The reemerging viruses maintained increasing progeny
virus production in successive passages, and two virus
strains, RVRp13 and RVRp22, were recovered at pas-
sages 13 and 22 in the presence of 0.1 and 0.2 mMribavirin, respectively. Ribavirin doses greater than or
equal to 0.3 mM completely suppressed the replication
of VR2332 below the detection limit of the virus titra-
tion assay for all 22 passages (Figure 2).
Growth kinetics of ribavirin-resistant mutants in the
presence of ribavirin at several concentrations
RVRp13 and RVRp22 were evaluated for their resistance
to ribavirin by assessing their growth competence in
MARC-145 cells in the presence of several concentra-
tions (0, 0.1, 0.2, 0.3, 0.4, and 0.5 mM) of ribavirin, com-
pared to the growth competence of the parental virus,
VR2332. Both mutant virus strains exhibited higher rep-
lication efficiency than did VR2332 in the presence of ri-
bavirin (Figure 3); RVRp13 and RVRp22 both replicated
over 10- or 100-times more efficiently than VR2332 in
the presence of 0.1 or 0.2 mM ribavirin, respectively.
Moreover, VR2332 was unable to replicate in the pres-
ence of ribavirin at concentrations of 0.2 mM or higher,
whereas RVRp13 and RVRp22 were able to grow to a
moderate extent in the presence of ribavirin at concen-
trations as high as 0.5 mM.
Higher genetic stability of ribavirin-resistant mutants after
serial passages in MARC-145 cells
The ribavirin-resistant mutants, RVRp13 and RVRp22,
and VR2332 were plaque-purified and designated as
RVRp13-p, RVRp22-p, and VR2332-p, respectively. The
plaque-purified viruses were then serially passaged 10
times in MARC-145 cells without ribavirin. After 10 pas-
sages, 15 virus clones were rescued from each super-
natant by plaque purification for each virus strain, and
Figure 1 Evaluation of the effects of four antiviral mutagens on PRRSV replication. The effects of different concentrations of ribavirin (A),
5-fluorouracil (C), 5-azacytidine (E), and amiloride (G) in RPMI-1640 medium on the replication of the PRRSV isolate VR2332 in MARC-145 cells
were evaluated, as determined by the production of progeny viruses (TCID50/ml) over time. Cytotoxicity assays were performed using cell culture
fluids collected from MARC-145 cells every 12 hours after being incubated with the following mutagens: ribavirin (B), 5-fluorouracil (D), 5-azacytidine
(F), and amiloride (H), as indicated in the panel. The results are expressed as the luminescence (RLU) from dead-cell protease activity. Asterisks represent
a significant difference (p < 0.05) in virus replication after mutagen treatment compared to that after vehicle treatment.
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virus clones were amplified for sequencing. As summa-
rized in Table 2 and Figure 4, RVRp13-p and RVRp22-p
exhibited lower mutation frequencies than VR2332-p
after 10 sequential passages in MARC-145 cells: 175 nu-
cleotide and 96 amino acid substitutions were identified
in the nsp2 region of VR2332-p, whereas RVRp13-p had98 nucleotide (p < 0.05) and 70 amino acid substitutions
(p < 0.05) and RVRp22-p had 51 nucleotide (p < 0.001)
and 24 amino acid substitutions (p < 0.001) in the same
region {Figure 4 (A)}. In ORF5, both RVRp13-p and
VR23323-p had similar mutation frequencies, with 57
nucleotide and 29 amino acid substitutions for RVRp13-
p and 51 nucleotide and 32 amino acid substitutions for
Figure 2 Emergence of ribavirin-resistant PRRSV mutants during sequential passages with ribavirin in MARC-145 cells. Ribavirin-resistant
mutants emerged during serial passages of the PRRSV isolate VR2332 in MARC-145 cells in the presence of different concentrations of ribavirin,
based on the presence or absence of detectable infectious progeny virus at the end of a 24-hour incubation.
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(p < 0.001) mutation frequency, accumulating only 6 nu-
cleotide and 4 amino acid substitutions {Figure 4 (B)}.
Discussion
In the current study, the possibility of rescuing a genet-
ically stable PRRSV mutant during sequential passages
in MARC-145 cells in the presence of mutagens was ex-
plored on the basis of previous reports that showed that
mutant viruses that emerged from lethal mutagenesis
driven by antiviral mutagens exhibited higher genetic
stability than wild-type viruses [35,41,43]. To choose the
most appropriate mutagen for the study, four different
antiviral mutagens (ribavirin, 5-fluorouracil, 5-azacytidine,
and amiloride) were evaluated for their antiviral effects
against PRRSV and for their cytotoxicity in MARC-145
cells. In the presence of ribavirin at concentrations
higher than 0.2 mM, the replication of VR2332 was
completely suppressed, whereas even at the highest con-
centration, 1.5 mM, ribavirin did not cause significant
cytotoxicity in MARC-145 cells {Figure 1 (A and B)}.
This result is in good agreement with previous studies
conducted to evaluate the antiviral effects of ribavirin
on several RNA viruses, including HCV, respiratory
syncytial virus (RSV), poliovirus, FMDV, and Influenza
A and B viruses [28,30,32,33,42,55-57]. Recently, ribavi-
rin was reported as a potential antiviral drug against
PRRSV because it reduced virus replication approxi-
mately 100 times in PAM-pCD163 cells when added at
a concentration of 0.05 mM, which was the highestconcentration applied in the study [58]. However, in the
current study, 0.05 mM ribavirin failed to suppress
PRRSV replication in MARC-145 cells, and concentra-
tions higher than 0.2 mM ribavirin were required for
complete suppression of PRRSV replication (Figure 2).
Unlike the results observed in PAM-pCD163 cells, no
significant cytotoxicity was observed in MARC-145
cells, even when treated with 1.5 mM ribavirin. Thus,
ribavirin-resistant mutant viruses were rescued in the
presence of ribavirin at concentrations as high as 0.1
and 0.2 mM. Similarly, 5-fluorouracil effectively sup-
pressed VR2332 replication in MARC-145 cells at con-
centrations ranging from 0.2 to 1 mM without causing
significant cytotoxicity {Figure 1 (C and D)}. The effect-
ive antiviral activity of 5-fluorouracil has also been re-
ported for rift valley fever virus, vesicular stomatitis
virus, poliovirus, and FMDV [26,59-63]. In contrast, 5-
azacytidine or amiloride at concentrations between 1
and 1.5 mM induced significant cytotoxicity in MARC-
145 cells, although concentrations of 5-azacytidine or
amiloride lower than 1 mM showed substantial antiviral
efficacy against PRRSV {Figure 1 (E and F) and Figure 1
(G and H)}. A previous study reported that 1 mM 5-
azacytidine caused significant cytotoxicity in 293 T and
U373-MAGICXCR4 cells 24 hours after treatment [46] al-
though a significant level of antiviral activity against
HIV-1 was reported with 5-azacytidine at concentra-
tions between 1 μM and 100 μM [45,46]. However, low
concentrations (<0.1 mM) of 5-azacytidine did not re-
sult in significant antiviral activity against PRRSV in the
Figure 3 (See legend on next page.)
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Figure 3 Assessment of the growth kinetics of ribavirin-resistant mutants in the presence of ribavirin. The growth kinetics of two
ribavirin-resistant PRRSV mutants (RVRp13 and RVRp22) were evaluated in MARC-145 cells in the presence of several concentrations of ribavirin
compared to their parental strain VR2332.
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ported that 1 mM amiloride was non-cytotoxic in HeLa
T cells for 48 hours post-treatment [38], which conflicts
with the results observed in this study showing that
substantial cytotoxicity was observed with 1–1.5 mM
amiloride in MARC-145 cells at 36 hours post-treatment
{Figure 1 (H)}. It was speculated that this dissimilarity
might be due to the different origins of the cell lines used
in the studies.
Based on the initial assessment of antiviral mutagens,
ribavirin was selected for further study to evaluate the
possible emergence of ribavirin-resistant mutants be-
cause it showed the greatest effect on PRRSV replication
without causing significant cytotoxicity even at the high-
est concentration (1.5 mM). Two ribavirin-resistant mu-
tants (RVRp13 and RVRp22) were isolated at passages
13 and 22 during serial passages of VR2332 in MARC-
145 cells in the presence of 0.1 and 0.2 mM ribavirin, re-
spectively (Figure 2). Previous studies also reported the
emergence of ribavirin-resistant mutants: ribavirin-
resistant HCV emerged after 7 passages in Huh7D cells
cultured with 0.25 mM ribavirin [42]. Similarly, ribavirin-
resistant CVB3, poliovirus, and FMDV emerged afterTable 2 Mutation frequencies of plaque-cloned, ribavirin-resis
after 10 passages in MARC-145 cells
Sequenced region
nsp2
Total no. of clones sequenceda
Total no. of nucleotides sequenced(3588 nt pe
Total no. of mutations
Total no. of nucleotide deletionsin sequenced
Mutation rate/103 nt
Total no. of amino acids sequenced(1196 aa p
Total no. of mutations
Total no. of amino acid deletionsin sequenced
Mutation rate/103 aa
ORF5
Total no. of clones sequenced
Total no. of nucleotides sequenced(603 nt per
Total no. of mutations
Mutation rate/103 nt
Total no. of amino acids sequenced(201 aa pe
Total no. of mutations
Mutation rate/103 aa
a: The numbers of nucleotide mutations and amino acid substitutions were determ
collected at the completion of 10 passages of each virus and comparing those sam
nt: nucleotide, aa: amino acid, significance levels when comparing a drug-resistantsequential passages in HeLa or BHK-21 cells cultured with
0.05-0.8 mM ribavirin [41,43,44].
The growth competence of the ribavirin-resistant mu-
tants RVRp13 and RVRp22 in MARC-145 cells was
assessed in the presence or absence of ribavirin. Both of
the ribavirin-resistant mutants showed approximately
10-100-times higher replication efficiency than VR2332
in the presence of 0.1 or 0.2 mM ribavirin. Moreover,
the replication of VR2332 was completely suppressed at
concentrations higher than 0.2 mM ribavirin, while both
mutants were able to generate infectious progeny vi-
ruses, reaching titers close to 103 TCID50/ml in the pres-
ence of 0.5 mM ribavirin (Figure 3). As reported in
many previous studies conducted with poliovirus [43],
human enterovirus 71 (HEV71) [64], FMDV [65,66],
coxsackie virus B3 [41] and HCV [42], enhanced resist-
ance of mutant viruses to ribavirin might be associated
with the increased genetic fidelity that is acquired during
viral passages in the presence of ribavirin. However, the
higher replication efficiency might also result from virus
adaptation to MARC-145 cells because the mutant vi-
ruses were rescued after 13 or 22 sequential passages. In
fact, the mutant viruses replicated more efficiently in thetant mutants (RVRp13-P and RVRp22-P) and VR2332-p
VR2332-p RVRp13-p RVRp22-p
15 15 15
r clone) 53820 53820 53820
175 98 51
length 63 0 6
3.25 1.82* 0.94**
er clone) 17940 17940 17940
96 70 24
length 21 0 2
5.35 3.90* 1.33**
15 15 15
clone) 9045 9045 9045
51 57 6
5.64 6.30 0.66**
r clone) 3015 3015 3015
32 29 4
10.61 9.61 1.32**
ined by sequencing 15 plaque-purified virus clones from cell culture fluids
ples to the original viruses not submitted to sequential cell passages.
strain with VR2332 are indicated by asterisks: *p < 0.05, **p < 0.001.
Figure 4 In vitro assessment of the genetic stability of ribavirin-resistant PRRSV mutants during serial passages in cells. The genetic
stability of the plaque-purified, ribavirin-resistant mutants (RVRp13-P and RVRp22-P) was compared with that of plaque-purified VR2332 (VR2332-p)
over 10 passages in MARC-145 cells. Fifteen viral clones obtained from cell culture fluids collected at the completion of 10 passages of each virus
by plaque purification and nsp2 (A) and ORF5 (B) regions of each virus clone were sequenced and compared with their parental viruses (RVRp13-P,
RVRp22-P, and VR2332-p) to determine nucleotide mutations (a) and amino acid (b) substitutions during the sequential passages. Asterisks represent
significant differences in the mutation rate compared with VR2332 (*p < 0.05, **p < 0.001).
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genetic stability of the ribavirin-resistant mutants was
assessed by passaging the mutant viruses 10 times in
MARC-145 cells without ribavirin in parallel with
VR2332 to demonstrate that ribavirin-resistant mutants
have increased genetic stability. The most variable genes
(nsp2 and ORF5) in the PRRSV genome were sequenced
to determine the mutation frequency of the viruses dur-
ing sequential passages. RVRp13 and RVRp22 virus
clones exhibited 1.8- and 3.4-fold lower numbers of nu-
cleotide substitutions and 1.4- and 4-fold lower numbers
of amino acid substitutions, respectively, in the nsp2 re-
gion compared with VR2332 virus clones {Table 2 and
Figure 4 (A)}. In the ORF5 region, the RVRp13 virus
clones exhibited mutation rates similar to those ob-
served in VR2332 virus clones, while RVRp22 virus
clones had approximately 8.5-fold lower numbers of nu-
cleotide substitutions and 8-fold lower numbers of
amino acid substitutions compared with VR2332 virus
clones {Table 2 and Figure 4 (B)}. Based on these results,
it was concluded that the ribavirin-resistant mutants, es-
pecially RVRp22, have significantly higher genetic stabil-
ity compared with their parental virus, VR2332.Conclusions
In conclusion, ribavirin was very effective in suppressing
PRRSV replication in MARC-145 cells at concentrations
higher than 0.2 mM, suggesting that ribavirin could be
used as a therapeutic drug against PRRSV; however, its
potential usefulness against PRRSV infection remains to
be confirmed in animal studies. As described in the
current study, the resistant viruses emerged in the pres-
ence of low concentrations (<0.2 mM) of ribavirin, and
those resistant viruses had significantly higher genetic
stability compared with VR2332. Because rapid reversion
of attenuated PRRS vaccines to virulence is of great con-
cern, RVRp22, which has a higher level of genetic stabil-
ity, could be a good candidate for the development of a
safer vaccine. Nonetheless, the mechanisms and genetic
determinants responsible for the high genetic stability of
ribavirin-resistant PRRSV should be elucidated in detail
in the near future.
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